Developer docs
API playgroundTry for free, no card

Search company profiles

Cellmover

Full company profile

uuid002fpsf

Namestring
Cellmover
Legal namestring
Cellmover AS
Websiteurl
cellmover.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Cellmover AS is a pre-clinical stage Norwegian biotechnology company developing nanobody- and peptide-based therapeutics for cancer immunotherapy. Founded in 2015 and headquartered in the ShareLab incubator at Oslo Science Park, the company has built a library of nanobodies and peptides directed at intracellular targets in T cells and NK cells — proteins that reside inside immune cells and were previously considered "undruggable" by conventional extracellular biologics. Cellmover's "Intracellular Biologics Platform" is designed to access the roughly 61% of the human proteome located intracellularly, with the goal of mediating increased survival and persistence of immune cells within the tumor microenvironment. Its pipeline comprises three named drug candidates — CM101 (in discovery), CM102 (lead optimization), and CM103 (lead optimization) — none of which have yet entered IND-enabling studies or clinical trials.

The company's business model is pre-revenue and centered on advancing its pipeline through preclinical and clinical development, with anticipated future monetization through licensing deals, strategic collaborations, or commercialization of successful therapeutic products with larger pharmaceutical partners. Business development is supported by an external BD Advisor (Eirik Næss-Ulseth). The company is privately held, founder-owned (Marit Inngjerdingen serves as Founder and Chairman), and funded through a mix of non-dilutive grants (Norwegian Research Council, Eurostars) and incubator support (ShareLab membership since May 2024; Aleap membership since October 2025). No institutional venture capital, private equity, or strategic investor ownership has been disclosed. The team consists of six core members including the founder/chairman, CEO, senior scientist, lab engineer, associate scientist, and BD advisor; a CEO transition occurred in November 2025 with Miriam Aarsund Larsen promoted from CSO to CEO.

Short descriptiontext

Cellmover AS is a pre-clinical Norwegian biotechnology company developing a proprietary library of nanobodies and peptides that target intracellular proteins in T cells and NK cells to enhance immune cell persistence in tumors for cancer immunotherapy.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersOslo, Norway
HQ citystring
Oslo
HQ countrystring
Norway
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nanobody therapeutics, cancer immunotherapy, intracellular biologics, preclinical drug development, immune cell engineering
Industry2 codes
PRIMARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cancer Immunotherapy / Biopharmaceuticals
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-revenue / Pipeline Development
TypeLicensing Royalties
Description

Cellmover is a pre-clinical stage immunotherapy company. As such, the company does not yet generate revenue. Its business model centers on developing a pipeline of nanobody-based therapeutic candidates (CM101, CM102, CM103) through preclinical and clinical stages, with anticipated future revenue derived from licensing deals, partnerships, or commercialization of successful therapeutic products.

cellmover.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Cellmover develops a proprietary library of nanobodies and peptides directed at intracellular targets in T cells and NK cells to enhance cancer immunotherapy. The company is advancing three preclinical drug candidates (CM101, CM102, CM103) targeting intracellular proteins in immune cells to improve survival and persistence within the tumor microenvironment.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Cellmover is a pre-clinical stage immunotherapy company developing a platform of nanobody and peptide-based drug candidates targeting intracellular proteins in immune cells. The company's portfolio includes three named drug candidates (CM101, CM102, CM103) in various stages of discovery through pre-clinical development. The technology aims to enhance cancer immunotherapy by improving immune cell survival and persistence within the tumor microenvironment.

Product and service3 records
1CM101
CategoryDrug candidate
Description

Lead preclinical drug candidate targeting specific intracellular proteins in T cells and NK cells for cancer immunotherapy. Currently in the discovery stage of preclinical development. Intended for future out-licensing or partnership with pharmaceutical companies.

2CM102
CategoryDrug candidate
Description

Second preclinical drug candidate targeting specific intracellular proteins in immune cells for cancer immunotherapy. Currently in lead optimization stage. Intended for future out-licensing or partnership with pharmaceutical companies.

3CM103
CategoryDrug candidate
Description

Third preclinical drug candidate targeting specific intracellular proteins in immune cells for cancer immunotherapy. Currently in lead optimization stage. Intended for future out-licensing or partnership with pharmaceutical companies.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-01
Description

Aleap is Norway's leading incubator for health and life science start-ups located at Oslo Science Park. Cellmover joined Aleap in October 2024 to gain access to industry experts, mentors, investors, and strategic guidance across regulatory, intellectual property, business development, and clinical operations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-01
Description

ShareLab is a biotech incubator at Oslo Science Park. Cellmover joined ShareLab in May 2024, describing it as a milestone for the company. ShareLab membership enables acceleration of R&D, opens opportunities for collaboration, and supports the company's mission to develop cancer immunotherapies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage NK cell therapy developer focused on engineered NK cells for oncology. Direct peer because Cellmover targets NK cells (alongside T cells) and aims to enhance NK cell persistence via nanobodies, conceptually adjacent to NKarta's engineered NK platform.

TypeDirect peer
Description

Clinical-stage leader in nanobody-based therapeutics (VHH antibody fragments) for immunology and oncology indications. Most directly comparable peer to Cellmover given shared nanobody scaffold focus and ambitions to expand into intracellular and previously undruggable target spaces.

TypeDirect peer
Description

Clinical-stage developer of T-cell engagers using a proprietary VH domain platform (T-cell enhancing Humabody). Closely analogous to Cellmover's nanobody-based approach for redirecting and enhancing T-cell function in cancer, sharing both scaffold class and modality.

TypeDirect peer
Description

Pioneering nanobody platform originally developed by Ablynx and acquired by Sanofi for ~$4.8B. Sets the architectural template for nanobody-based therapeutic development that Cellmover's platform follows and validates the commercial potential of nanobody-based franchises.

TypeDirect peer
Description

Developed T-cell engagers using a proprietary tri-specific T-cell activating construct (TriTAC) platform for solid tumors, acquired by Merck for ~$680M. Comparable peer as another engineered approach to T-cell engagement in oncology that validates pharma appetite for novel T-cell-focused platforms.

TypeEmerging player
Description

Clinical-stage bispecific antibody developer with oncology programs designed to enhance immune cell engagement against tumors. Emerging peer with a complementary engineered-protein approach to T-cell redirection in oncology.

TypeDirect peer
Description

Clinical-stage allogeneic CAR-T developer advancing off-the-shelf cell therapies for cancer. Relevant peer given overlapping T-cell oncology focus and shared emphasis on improving persistence and efficacy of engineered immune cells in solid tumors.

TypeDirect peer
Description

Develops engineered T-cell receptor (TCR) therapies for solid tumors. Operates in the same addressable space of enhancing T-cell persistence and efficacy in the tumor microenvironment that Cellmover's intracellular nanobody approach addresses, serving as a benchmark for T-cell-directed oncology therapeutics.

TypeRegional player
Description

European (UK/Switzerland) small-molecule immuno-oncology company. Regional emerging peer illustrating the European biotech competitive landscape for cancer immunotherapy developers of similar early-stage scale to Cellmover.

TypeBroad incumbent
Description

Pioneer of BiTE (bispecific T-cell engager) technology, acquired by Amgen for ~$1.2B; blinatumomab is approved for ALL. Broad incumbent showing clinical proof of concept for T-cell-engaging modalities in oncology that informs the commercial context for novel platforms like Cellmover's.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cellmover

Cancer Immunotherapy / Biopharmaceuticalscellmover.com

Cellmover AS is a pre-clinical Norwegian biotechnology company developing a proprietary library of nanobodies and peptides that target intracellular proteins in T cells and NK cells to enhance immune cell persistence in tumors for cancer immunotherapy.

What Cellmover does

Cellmover AS is a pre-clinical stage Norwegian biotechnology company developing nanobody- and peptide-based therapeutics for cancer immunotherapy. Founded in 2015 and headquartered in the ShareLab incubator at Oslo Science Park, the company has built a library of nanobodies and peptides directed at intracellular targets in T cells and NK cells — proteins that reside inside immune cells and were previously considered "undruggable" by conventional extracellular biologics. Cellmover's "Intracellular Biologics Platform" is designed to access the roughly 61% of the human proteome located intracellularly, with the goal of mediating increased survival and persistence of immune cells within the tumor microenvironment. Its pipeline comprises three named drug candidates — CM101 (in discovery), CM102 (lead optimization), and CM103 (lead optimization) — none of which have yet entered IND-enabling studies or clinical trials.

The company's business model is pre-revenue and centered on advancing its pipeline through preclinical and clinical development, with anticipated future monetization through licensing deals, strategic collaborations, or commercialization of successful therapeutic products with larger pharmaceutical partners. Business development is supported by an external BD Advisor (Eirik Næss-Ulseth). The company is privately held, founder-owned (Marit Inngjerdingen serves as Founder and Chairman), and funded through a mix of non-dilutive grants (Norwegian Research Council, Eurostars) and incubator support (ShareLab membership since May 2024; Aleap membership since October 2025). No institutional venture capital, private equity, or strategic investor ownership has been disclosed. The team consists of six core members including the founder/chairman, CEO, senior scientist, lab engineer, associate scientist, and BD advisor; a CEO transition occurred in November 2025 with Miriam Aarsund Larsen promoted from CSO to CEO.

Cellmover firmographics

Firmographics
Name
Cellmover
Legal name
Cellmover AS
Website
https://cellmover.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Cellmover AS is a pre-clinical Norwegian biotechnology company developing a proprietary library of nanobodies and peptides that target intracellular proteins in T cells and NK cells to enhance immune cell persistence in tumors for cancer immunotherapy.
Ownership category
akta.pro rank

Cellmover industry classification

Industry
Product category
Cancer Immunotherapy / Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Nanobody therapeutics
  • Cancer immunotherapy
  • Intracellular biologics
  • Preclinical drug development
  • Immune cell engineering

Where Cellmover is headquartered

Location

Headquarters

HQ city
Oslo
HQ country
Norway
HQ region
Europe

Offices1 record

Markets served

Cellmover business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Revenue model

  1. Pre-revenue / Pipeline Development: Cellmover is a pre-clinical stage immunotherapy company. As such, the company does not yet generate revenue. Its business model centers on developing a pipeline of nanobody-based therapeutic candidates (CM101, CM102, CM103) through preclinical and clinical stages, with anticipated future revenue derived from licensing deals, partnerships, or commercialization of successful therapeutic products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Cellmover product offering

Product offering

Core offering

Cellmover develops a proprietary library of nanobodies and peptides directed at intracellular targets in T cells and NK cells to enhance cancer immunotherapy. The company is advancing three preclinical drug candidates (CM101, CM102, CM103) targeting intracellular proteins in immune cells to improve survival and persistence within the tumor microenvironment.

Product overview

Cellmover is a pre-clinical stage immunotherapy company developing a platform of nanobody and peptide-based drug candidates targeting intracellular proteins in immune cells. The company's portfolio includes three named drug candidates (CM101, CM102, CM103) in various stages of discovery through pre-clinical development. The technology aims to enhance cancer immunotherapy by improving immune cell survival and persistence within the tumor microenvironment.

Differentiator

Problem solved

Functional benefit

Products and services

  • CM101 Lead preclinical drug candidate targeting specific intracellular proteins in T cells and NK cells for cancer immunotherapy. Currently in the discovery stage of preclinical development. Intended for future out-licensing or partnership with pharmaceutical companies.
  • CM102 Second preclinical drug candidate targeting specific intracellular proteins in immune cells for cancer immunotherapy. Currently in lead optimization stage. Intended for future out-licensing or partnership with pharmaceutical companies.
  • CM103 Third preclinical drug candidate targeting specific intracellular proteins in immune cells for cancer immunotherapy. Currently in lead optimization stage. Intended for future out-licensing or partnership with pharmaceutical companies.

Companies that use Cellmover

Customer profile

Segments1 record

Ideal customer profiles1 record

Cellmover technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Cellmover partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • AleapcoreStrategic or Co-development Partner · 1 October 2024Aleap is Norway's leading incubator for health and life science start-ups located at Oslo Science Park. Cellmover joined Aleap in October 2024 to gain access to industry experts, mentors, investors, and strategic guidance across regulatory, intellectual property, business development, and clinical operations.
  • ShareLabcoreStrategic or Co-development Partner · 1 May 2024ShareLab is a biotech incubator at Oslo Science Park. Cellmover joined ShareLab in May 2024, describing it as a milestone for the company. ShareLab membership enables acceleration of R&D, opens opportunities for collaboration, and supports the company's mission to develop cancer immunotherapies.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Cellmover competitors and assessment

Company assessment

Direct peers

  • Nkarta Therapeutics: Clinical-stage NK cell therapy developer focused on engineered NK cells for oncology. Direct peer because Cellmover targets NK cells (alongside T cells) and aims to enhance NK cell persistence via nanobodies, conceptually adjacent to NKarta's engineered NK platform.
  • argenx: Clinical-stage leader in nanobody-based therapeutics (VHH antibody fragments) for immunology and oncology indications. Most directly comparable peer to Cellmover given shared nanobody scaffold focus and ambitions to expand into intracellular and previously undruggable target spaces.
  • Crescendo Biologics: Clinical-stage developer of T-cell engagers using a proprietary VH domain platform (T-cell enhancing Humabody). Closely analogous to Cellmover's nanobody-based approach for redirecting and enhancing T-cell function in cancer, sharing both scaffold class and modality.
  • Ablynx (Sanofi): Pioneering nanobody platform originally developed by Ablynx and acquired by Sanofi for ~$4.8B. Sets the architectural template for nanobody-based therapeutic development that Cellmover's platform follows and validates the commercial potential of nanobody-based franchises.
  • Harpoon Therapeutics (now Merck): Developed T-cell engagers using a proprietary tri-specific T-cell activating construct (TriTAC) platform for solid tumors, acquired by Merck for ~$680M. Comparable peer as another engineered approach to T-cell engagement in oncology that validates pharma appetite for novel T-cell-focused platforms.
  • Allogene Therapeutics: Clinical-stage allogeneic CAR-T developer advancing off-the-shelf cell therapies for cancer. Relevant peer given overlapping T-cell oncology focus and shared emphasis on improving persistence and efficacy of engineered immune cells in solid tumors.
  • Adaptimmune: Develops engineered T-cell receptor (TCR) therapies for solid tumors. Operates in the same addressable space of enhancing T-cell persistence and efficacy in the tumor microenvironment that Cellmover's intracellular nanobody approach addresses, serving as a benchmark for T-cell-directed oncology therapeutics.

Emerging players

  • Compass Therapeutics: Clinical-stage bispecific antibody developer with oncology programs designed to enhance immune cell engagement against tumors. Emerging peer with a complementary engineered-protein approach to T-cell redirection in oncology.

Regional players

  • NeoPhore: European (UK/Switzerland) small-molecule immuno-oncology company. Regional emerging peer illustrating the European biotech competitive landscape for cancer immunotherapy developers of similar early-stage scale to Cellmover.

Broad incumbents

  • Micromet / blinatumomab (Amgen): Pioneer of BiTE (bispecific T-cell engager) technology, acquired by Amgen for ~$1.2B; blinatumomab is approved for ALL. Broad incumbent showing clinical proof of concept for T-cell-engaging modalities in oncology that informs the commercial context for novel platforms like Cellmover's.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Cellmover social profiles

Digital presence

Cellmover financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cellmover leadership team

Management profile

Number of profiles

Profiles6 records

Cellmover funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cellmover M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellmover

What does Cellmover do?

Cellmover develops a proprietary library of nanobodies and peptides directed at intracellular targets in T cells and NK cells to enhance cancer immunotherapy. The company is advancing three preclinical drug candidates (CM101, CM102, CM103) targeting intracellular proteins in immune cells to improve survival and persistence within the tumor microenvironment.

Is Cellmover a public or private company?

Cellmover is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Cellmover founded?

Cellmover was founded in 2015. It employs 1 to 10 people.

Where is Cellmover based?

Cellmover is headquartered in Oslo, Norway, in the Europe region.

How does Cellmover make money?

One revenue line is on record: pre-revenue / Pipeline Development.

Who are Cellmover's main competitors?

Direct peers on record are Nkarta Therapeutics, argenx, Crescendo Biologics, Ablynx (Sanofi), Harpoon Therapeutics (now Merck), Allogene Therapeutics and Adaptimmune. Compass Therapeutics is listed as an emerging player. NeoPhore is listed as a regional player. Micromet / blinatumomab (Amgen) is listed as a broad incumbent.

Does Cellmover have an API?

No public API is recorded for Cellmover.

What industry is Cellmover in?

Cellmover's product category is Cancer Immunotherapy / Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish), with a secondary code of HLAAABAD, NK Cell Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales